US-based prescription platform ZappRx has closed a $5.6m series A round backed by investors including SR One, the corporate venturing arm of healthcare company GlaxoSmithKline, TechCrunch has reported.
The round also included venture capital firm Atlas Venture, which took part in ZappRx’s $1m seed round in January 2014 alongside SR One and angel investors including Terry Meguid, David Hamamoto, Sean Trigony and James Glimm.
Founded in 2012, ZappRx has developed a platform through which health care providers, patients and pharmacists can interact and communicate with each other.
When a care provider writes an e-prescription using ZappRx, the patient will instantly receive the prescription on his or her smartphone that they can fill, transfer or renew.
The company has raised $8.8m in total, according to TechCrunch. Atlas Venture and angel investment group Life Sciences Angel Network were the investors in its initial seed round in 2013.
The funding will go toward helping to build the startup’s prescription data automation technology and expanding its team from 17 to 32.